Recombinant chimeric antigen used for the prevention or treatment of infections caused by Anaplasma phagocytophilum.
Monitor and reduce pathological tremors in users through a neuroprosthetic system able to stimulate patient´s affected pathways.
Nanoemulsions composed of an oil core and a surfactant coating, in combination with an antimicrobial peptide, which inhibit the formation of bacterial biofilms and can therefore be used for the treatment or prevention of diseases or contamination of surfaces.
New bacterial strain with a high capacity to capture CO2 and transform it into added-value nanocellulose. In addition, it produces nanocellulose from different types of agro-industrial waste, including crude glycerin residue from biodiesel production, sugar molasses, whey, etc...
This device provides a suitable method for the capture, detection and identification of whole airborne biological particles, including viruses (such as SARS-CoV-2) and other pathogens.
Isolation from the intestine of a healthy woman a novel bacteria strain that produces urolithins and development of a novel gut bacterial consortia comprising the mentioned novel bacterium and other bacteria wherein the consortia produce the mix of urolithins of metabotypes A or B, respectively, either in vitro or in vivo, including the newly characterized urolithin G.
New carbon nanocapsules filled with enriched lithium compounds that can be applied in NCT for cancer treatment
In vitro method to assess the fertilizing capacity of spermatozoa and select those of better quality and with the ability to penetrate the zona pellucida (ZP) of the oocyte and fertilize it.
Two different vaccines prototypes have been developed based on RNA replicons from SARS-CoV-2 and MERS-CoV, encapsulated in Virus-Like Particles (VLPs), which can be used as a vaccines to generate immunity and protect against infections by these coronavirus.
A panel of high affinity nanobodies (Nb) binding to diverse SARS-CoV-2 RBD epitopes of spike protein, and a set of nanobody-derived neutralizing heavy chain antibodies (hcAbs) have been identified. They have potential as therapy against SRAS-CoV-2 for immunocompromised or non-responding to vaccines individuals.